GCI

1st October 2021
13:00

Vectura Group plc - Director/PDMR Shareholding

1st October 2021
09:48

Vectura Group plc - Total Voting Rights

1st October 2021
06:00

Philip Morris Int - Offer Update

1st October 2021
06:00

Philip Morris Int - Offer Update

30th September 2021
12:23

Vectura Group plc - Additional Listing

30th September 2021
06:00

Vectura Group plc - Rule 2.9 Announcement

24th September 2021
09:20

Vectura Group plc - Additional Listing

21st September 2021
06:00

Vectura Group plc - Rule 2.9 Announcement

20th September 2021
12:13

Vectura Group plc - Director/PDMR Shareholding

20th September 2021
08:53

Vectura Group plc - Additional Listing

20th September 2021
06:00

Philip Morris Int - Delisting of Vectura

17th September 2021
06:00

Vectura Group plc - Rule 2.9 Announcement

16th September 2021
16:30

FTSE Russell - Vectura Group

16th September 2021
06:00

Philip Morris Int - Offer becomes unconditional in all respects

15th September 2021
10:33

J.P. Morgan AG - Form 8.5 (EPT/NON-RI)- Vectura Group plc

14th September 2021
15:55

Philip Morris Int - Satisfaction of Japanese Antitrust Condition

10th September 2021
10:30

BkofA Merrill Lynch - Form 8.5 (EPT/NON-RI)

9th September 2021
10:40

J.P. Morgan AG - Form 8.5 (EPT/NON-RI)-Vectura Group plc

9th September 2021
09:28

Norges Bank - Form 8.3 - Vectura Group Plc

8th September 2021
11:32

Norges Bank - Form 8.3 - Vectura Group Plc

Vectura Group Plc (VEC.L) Share Price & News

Bid

-

-

-

Ask

High
-
OPEN
-
VOL
-
MKT CAP
-M

LOW
-
CLOSE
-
SHARES IN ISSUE
596.14M

Vectura Group Plc Company Profile

Vectura develops inhaled therapies principally for the treatment of respiratory diseases.

Watchlist